MAP kinase-activated protein kinase 2 (MK2) (MK2)

MAP kinase-activated protein kinase 2 (MK2) is a serine/threonine-protein kinase that serves as a primary downstream effector of the p38 mitogen-activated protein kinase (MAPK) signaling pathway. It plays a pivotal role in the inflammatory response by post-transcriptionally regulating the stability and translation of mRNAs containing adenylate-uridylate-rich elements (AREs), such as those encoding tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6). Beyond inflammation, MK2 is involved in cell cycle control, particularly the G2/M checkpoint, as well as DNA damage response, cytoskeleton remodeling, and cell migration. In the context of disease, MK2 is a major driver of chronic inflammatory conditions like rheumatoid arthritis and psoriasis, and it has been implicated in cancer progression and chemoresistance. Therapeutic strategies targeting MK2, such as the small molecule zunsemetinib (ATI-450), aim to provide a safer alternative to p38 inhibitors by selectively blocking proinflammatory signaling while sparing anti-inflammatory feedback loops. These inhibitors are currently being evaluated in clinical trials for their ability to reduce systemic inflammation and enhance the efficacy of chemotherapeutic agents. MK2 also regulates the phosphorylation of heat shock protein 27 (HSP27), which is a key biomarker for monitoring the efficacy of MK2-targeted therapies. The development of MK2 inhibitors has faced challenges such as low biochemical efficiency and selectivity, but non-ATP-competitive approaches show promise in overcoming these hurdles.

Other names

MAPKAPK2MAPKAP kinase 2MAPKAP-K2MK-2Mitogen-activated protein kinase-activated protein kinase 2

MK2 inhibitors primarily function by blocking the kinase activity of MAP kinase-activated protein kinase 2, either through ATP-competitive inhibition or by targeting the p38/MK2 complex interface. This inhibition prevents the phosphorylation of downstream substrates like heat shock protein 27 (HSP27) and tristetraprolin (TTP). By inhibiting TTP phosphorylation, MK2 inhibitors promote the degradation of AU-rich element (ARE)-containing mRNAs, thereby reducing the production of proinflammatory cytokines such as TNF-alpha, IL-1 beta, and IL-6.